FDA's early-stage clinical trial program, a mysterious single patient gets retatrutide access, and more health news from Morning Rounds
Vetenskapsnyheter
Digital health startup Cadence has raised $100 million at a $1.23 billion valuation to expand its chronic disease management program.
A new gene-editing startup negotiated contracts with a Chinese company, raised $230 million in funding, and executed a reverse-merger with a preexisting biotech company.
If the Supreme Court upholds the executive order ending birthright citizenship, it could “have stark consequences at the intersection of bioethics and public health.”
Exclusive: STAT has learned that Eli Lilly and the FDA allowed a 79-year-old to gain extraordinary access to an experimental obesity drug through the agency’s “compassionate use” program.
EchoNext, a new AI tool cleared by the FDA, will let doctors use an EKG to easily screen patients for structural heart diseases.
“There's a particular cruelty buried in the new Medicaid work requirement rules,” write Maria Town and Nicole Jorwic.
A new memo from the Department of Justice seeks to upend landmark disability laws and court rulings.
Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer fell short in a clinical trial.
Federal health officials aim to speed up drug development and better compete with China.
Confirmed cases in the Ebola outbreak in eastern Congo have reached 1,003, including 254 deaths, officials said, as tracing those who had been in contact with patients remains a major challenge.
AbbVie buys Apogee Therapeutics, LSD therapy Phase 3 results, and more biotech news from The Readout
An NIH grant proposal poses new threats, more cases of a livestock disease in Europe, and more health news from Morning Rounds
The latest pharma news from the Pharmalot campus via the Pharmalittle newsletter is here
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval.
The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four months ago.
Health disparities researchers say a new White House proposal could disqualify much of their work from federal funding — perhaps the most serious threat yet to the future of their…
“Nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are still asked to provide it.”
The psychiatric ER is “a detox center for those with no safe place to withdraw and a respite center for caregivers at their breaking point,” writes a psychiatrist.
Pharmaceutical companies are hungry to make deals, and they’re making more than they have in years.
Sanofi said that Paulo Fontoura, the chief medical officer at Xaira, would be taking over as its head of R&D, as the company tries to jumpstart its pipeline.
When STAT polled our readers on ‘health care’ vs. ‘healthcare,’ about 60% of our readers voted for one word.
Keep those letters coming!
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.